期刊
CANCER CHEMOTHERAPY AND PHARMACOLOGY
卷 81, 期 6, 页码 1007-1015出版社
SPRINGER
DOI: 10.1007/s00280-018-3576-x
关键词
Advanced gastric cancer; Paclitaxel; Oxaliplatin; Combination chemotherapy
资金
- Foundation of Medical Innovation Project in Fujian Province [2016-CX-26]
This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with Paclitaxel (PTX) and Oxaliplatin (OXA) as first-line treatment for patients with advanced gastric cancer (AGC). One hundred and seven patients with locally advanced or metastatic gastric adenocarcinoma received intravenous infusions of PTX at 135 mg/m(2) and OXA at 85 mg/m(2) on day 1 every 14 days. Among 107 patients enrolled, 9 patients could not be evaluated for a response because of the absence of any measurable lesions. Assessment of the response of 98 patients was made. The overall objective response rate was 42.9% (95% CI 32.9-52.8%), with two complete responses and 40 partial responses. The disease control was 79.6% (95% CI 71.5-87.7%). With 29 months of the median time of follow-up, the median progression-free survival was 5.8 months (95% CI 4.30-7.30 months) and the median overall survival was 11.5 months (95% CI 9.08-13.9 months). The 1-year survival rate was 48.0%. The most common grades 3 and 4 toxicities included neutropenia (32.7%), leucopenia (17.8%), fatigue (5.61%), and anemia (4.67%). Peripheral neuropathy occurred in 23.4% patients and grade 2 or higher peripheral neuropathy occurred in 12.1% of the patients. Combination chemotherapy with PTX and OXA offers a new, effective and safe regimen for patients with advanced gastric cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据